PTN Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -- compared to Palatin Technologies's net margin of -14.12%. Palatin Technologies's return on equity of -- beat Alnylam Pharmaceuticals's return on equity of --.

Palatin Technologies has a consensus price target of --, signalling upside risk potential of 1557.59%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $315.33 which suggests that it could grow by 36.8%. Given that Palatin Technologies has higher upside potential than Alnylam Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Alnylam Pharmaceuticals.

Palatin Technologies has a beta of 0.896, which suggesting that the stock is 10.45% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.047%.

Palatin Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palatin Technologies pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Palatin Technologies quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Palatin Technologies's net income of -- is lower than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Palatin Technologies's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palatin Technologies is -- versus 13.09x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of -- compared to Palatin Technologies's net margin of -34.13%. Palatin Technologies's return on equity of -- beat Blueprint Medicines's return on equity of -24.43%.

Palatin Technologies has a consensus price target of --, signalling upside risk potential of 1557.59%. On the other hand Blueprint Medicines has an analysts' consensus of $124.90 which suggests that it could grow by 52.11%. Given that Palatin Technologies has higher upside potential than Blueprint Medicines, analysts believe Palatin Technologies is more attractive than Blueprint Medicines.

Palatin Technologies has a beta of 0.896, which suggesting that the stock is 10.45% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.37%.

Palatin Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palatin Technologies pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Palatin Technologies quarterly revenues are --, which are smaller than Blueprint Medicines quarterly revenues of $146.4M. Palatin Technologies's net income of -- is lower than Blueprint Medicines's net income of -$50M. Notably, Palatin Technologies's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palatin Technologies is -- versus 10.23x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Organon & has a net margin of -- compared to Palatin Technologies's net margin of 6.85%. Palatin Technologies's return on equity of -- beat Organon &'s return on equity of 397.42%.

Palatin Technologies has a consensus price target of --, signalling upside risk potential of 1557.59%. On the other hand Organon & has an analysts' consensus of $20.00 which suggests that it could grow by 84.84%. Given that Palatin Technologies has higher upside potential than Organon &, analysts believe Palatin Technologies is more attractive than Organon &.

Palatin Technologies has a beta of 0.896, which suggesting that the stock is 10.45% less volatile than S&P 500. In comparison Organon & has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Palatin Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & offers a yield of 10.35% to investors and pays a quarterly dividend of $0.28 per share. Palatin Technologies pays -- of its earnings as a dividend. Organon & pays out 34.38% of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Palatin Technologies quarterly revenues are --, which are smaller than Organon & quarterly revenues of $1.6B. Palatin Technologies's net income of -- is lower than Organon &'s net income of $109M. Notably, Palatin Technologies's price-to-earnings ratio is -- while Organon &'s PE ratio is 3.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palatin Technologies is -- versus 0.44x for Organon &. Usually stocks with elevated PS ratios are considered overvalued.

Third Harmonic Bio has a net margin of -- compared to Palatin Technologies's net margin of --. Palatin Technologies's return on equity of -- beat Third Harmonic Bio's return on equity of --.

Palatin Technologies has a consensus price target of --, signalling upside risk potential of 1557.59%. On the other hand Third Harmonic Bio has an analysts' consensus of $4.68 which suggests that it could fall by -8.72%. Given that Palatin Technologies has higher upside potential than Third Harmonic Bio, analysts believe Palatin Technologies is more attractive than Third Harmonic Bio.

Palatin Technologies has a beta of 0.896, which suggesting that the stock is 10.45% less volatile than S&P 500. In comparison Third Harmonic Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Palatin Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Third Harmonic Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palatin Technologies pays -- of its earnings as a dividend. Third Harmonic Bio pays out -- of its earnings as a dividend.

Palatin Technologies quarterly revenues are --, which are smaller than Third Harmonic Bio quarterly revenues of --. Palatin Technologies's net income of -- is lower than Third Harmonic Bio's net income of -$13.1M. Notably, Palatin Technologies's price-to-earnings ratio is -- while Third Harmonic Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palatin Technologies is -- versus -- for Third Harmonic Bio. Usually stocks with elevated PS ratios are considered overvalued.